ClinicalTrials.gg
Not yet recruitingNCT07550621Updated Apr 24, 2026

Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

A Phase 1 interventional study of MDR-001 and Rifampin in Healthy Volunteers (HV), sponsored by MindRank AI Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by MindRank AI Ltd · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Phase I, open-label, fixed-sequence, two-part drug-drug interaction study in healthy Chinese adults to evaluate the effect of multiple-dose rifampin (Part A) or itraconazole (Part B) on the single-dose pharmacokinetics of MDR-001, an oral GLP-1 receptor agonist.

Read the detailed description

This phase 1, single-center, open-label, fixed-sequence drug-drug interaction study will evaluate the effect of multiple-dose rifampicin (a strong CYP3A4 inducer) and multiple-dose itraconazole (a strong CYP3A4 inhibitor) on the single-dose pharmacokinetics of MDR-001, an oral small-molecule GLP-1 receptor agonist being developed for weight management. The study plans to enroll 28 healthy Chinese adults (18-55 years, BMI 18-28 kg/m²), with 12 participants in Part A (rifampicin) and 16 in Part B (itraconazole). The primary outcomes are the effects of rifampicin and itraconazole on Cmax, AUC0-t, and AUC0-∞ of MDR-001. Secondary outcomes include safety and tolerability (adverse events, vital signs, ECG, laboratory tests) and comparison of other pharmacokinetic parameters (Tmax, t1/2, MRT, CL/F, Vd/F, λz) between MDR-001 alone and combined with the interacting drugs.

02

Conditions studied

  • Healthy Volunteers (HV)

Keywords

  • MDR-001
  • GLP-1 receptor agonist
  • Drug-drug interaction (DDI)
  • Rifampin
  • Itraconazole
  • CYP3A4 inducer
  • CYP3A4 inhibitor
  • Pharmacokinetics (PK)
  • Healthy volunteers
03

In context

Lead sponsor

MindRank AI Ltd is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation and signed before any study procedures, with full understanding of the study content, procedures, and potential adverse reactions.
  • Healthy Chinese adult males or females aged 18 to 55 years (inclusive).
  • Body weight ≥50 kg for males and ≥45 kg for females, and (BMI) between 18 and 28 kg/m² (inclusive).
  • Judged by the investigator to be in good health, with medical history, laboratory tests, physical examination, vital signs, and results being normal or abnormal without clinical significance.
  • Participants and their partners must have no pregnancy plan and agree to use effective non-drug measures (e.g., condoms, non-medicated intrauterine devices) from 2 weeks before screening until 6 months after the end of the study, unless permanent sterilization has been performed (e.g., bilateral tubal ligation, vasectomy).
  • Willing to comply with the visit schedule, study treatment, laboratory tests, and other study-related procedures and requirements as specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Average daily smoking >5 cigarettes within 3 months before dosing.
  • History of headaches (e.g., migraine, tension-type headache).
  • Allergic constitution (multiple drug or food allergies) or intolerance/allergy to the active ingredient or of the study drugs.
  • History of alcohol abuse (≥14 units of alcohol per week; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine).
  • History of drug abuse or use of illicit drugs within 5 years before dosing.
  • Blood donation or significant blood loss (≥400 mL) within 3 months before dosing, or planned blood donation during the study.
  • Any disease that increases bleeding risk, such as acute gastritis or gastric/duodenal ulcer.
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or genetic conditions predisposing to MTC.
  • History of pancreatitis or symptomatic gallbladder disease.
  • Serum calcitonin > (ULN) at screening.
  • Dysphagia, or gastrointestinal disorders affecting absorption (e.g., diarrhea, vomiting, inflammatory bowel disease, active ulcer), or history of gastrointestinal surgery leading to malabsorption, or long-term use of drugs affecting gastrointestinal motility (e.g., bariatric surgery such as gastric banding).
  • Special dietary requirements and unable to accept standardized meals.
  • Surgery within 3 months before dosing, or planned surgery during the study, or surgery that affects drug absorption, distribution, metabolism, or excretion.
  • Received within 1 month before dosing, or planned vaccination during the study.
  • Use of any prescription drug, over-the-counter drug, vitamin product, or herbal medicine within 14 days before dosing.
  • Significant changes in diet or exercise habits within 3 months before dosing.
  • Use of inhibitors, CYP3A4 inducers, or P-gp inhibitors within 14 days before the first dose, or planned use during the study.
  • Participation in another clinical trial or receipt of an drug within 3 months before dosing (unless the participant withdrew before treatment/randomization).
  • abnormalities with clinical significance at screening; >450 msec (males) or >470 msec (females) by Fridericia's correction.
  • Pregnant, lactating, or positive pregnancy test in females of .
  • laboratory abnormalities, or clinically significant diseases within 12 months before dosing (respiratory, circulatory, digestive, endocrine, rheumatic/immune, nervous, hematologic, or psychiatric disorders) that make the participant unsuitable for the study.
  • Positive screening for surface antigen, antibody/core antigen, antibody, or syphilis antibody.
  • Acute illness or concomitant medication between screening and first dose.
  • Positive alcohol breath test or urine drug screen.
  • Any other condition judged by the investigator as unsuitable for participation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Part A (Rifampin Arm)

    Participants receive a single oral dose of MDR-001 alone on Day 1. then rifampin from Day 3 to Day 11, with a second single dose of MDR-001 co-administered on Day 10.

    Drug: MDR-001 · Drug: Rifampin

  • Experimental
    Part B (Itraconazole Arm)

    Participants receive a single oral dose of MDR-001alone on Day 1. , then receive itraconazole once daily from Day 3 to Day 8, with a second single dose of MDR-001 co-administered on Day 7.

    Drug: MDR-001 · Drug: Itraconazole

Interventions

  • Oral small-molecule GLP-1 receptor agonist ;Investigational drug (not yet approved)

  • Strong CYP3A4 inducer; Marketed anti-tuberculosis drug

  • Strong CYP3A4 inhibitor; Marketed antifungal drug

06

What researchers measure

Primary outcomes

  1. Cmax of MDR-001

    Maximum observed plasma concentration of MDR-001 after single-dose administration alone and in combination with rifampin (Part A) or itraconazole (Part B).

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  2. AUC0-t of MDR-001

    Area under the plasma concentration-time curve from time zero to the last measurable concentration after single-dose administration alone and in combination.

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  3. AUC0-∞ of MDR-001

    Area under the plasma concentration-time curve from time zero extrapolated to infinity after single-dose administration alone and in combinatio

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

Secondary outcomes

  1. Other Pharmacokinetic Parameters of MDR-001

    Tmax (time to reach Cmax) when administered alone vs. in combination.

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  2. Other Pharmacokinetic Parameters of MDR-001

    t1/2 (terminal elimination half-life) when administered alone vs. in combination.

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  3. Other Pharmacokinetic Parameters of MDR-001

    MRT (mean residence time) when administered alone vs. in combination.

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  4. Other Pharmacokinetic Parameters of MDR-001

    CL/F (apparent clearance) when administered alone vs. in combination.

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  5. Other Pharmacokinetic Parameters of MDR-001

    Vd/F (apparent volume of distribution) when administered alone vs. in combination.

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  6. Other Pharmacokinetic Parameters of MDR-001

    λz (terminal elimination rate constant) when administered alone vs. in combination.

    Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).

  7. Safety and Tolerability - Adverse Events

    Incidence, severity, and causality of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESI: grade ≥2 gastrointestinal events, grade 3 hypoglycemia, acute pancreatitis, thyroid C-cell tumors).

    Time frame: From first dose of study drug (Day 1) through follow-up phone call (Day 19 ±2 for Part A, Day 16 ±2 for Part B).

  8. Safety and Tolerability - Clinical Laboratory Tests

    Clinically significant changes from baseline in hematology parameters as measured by complete blood cell count with differential,

    Time frame: Screening, Day -1, Day 3, Day 6 (Part A only), Day 10 or 7 (co-administration day), and Day 12 or 9 (discharge) or early termination.

  9. Safety and Tolerability - Clinical Laboratory Tests

    Clinically significant changes from baseline in serum chemistry tests

    Time frame: Screening, Day -1, Day 3, Day 6 (Part A only), Day 10 or 7 (co-administration day), and Day 12 or 9 (discharge) or early termination.

  10. Safety and Tolerability - Clinical Laboratory Tests

    Clinically significant changes from baseline in coagulation tests.

    Time frame: Screening, Day -1, Day 3, Day 6 (Part A only), Day 10 or 7 (co-administration day), and Day 12 or 9 (discharge) or early termination.

  11. Safety and Tolerability - Clinical Laboratory Tests

    Clinically significant changes from baseline in urinalysis

    Time frame: Screening, Day -1, Day 3, Day 6 (Part A only), Day 10 or 7 (co-administration day), and Day 12 or 9 (discharge) or early termination.

  12. Safety and Tolerability - Clinical Laboratory Tests

    Clinically significant changes from baseline in thyroid function tests.

    Time frame: Screening, Day -1, Day 3, Day 6 (Part A only), Day 10 or 7 (co-administration day), and Day 12 or 9 (discharge) or early termination.

  13. Safety and Tolerability - 12 Lead ECG

    Changes from baseline in PR interval

    Time frame: Screening, Day -1, Day 1 (pre-dose and 2h post-dose), Day 3, Day 6 (Part A), Day 10 or 7 (pre-dose and 2h post-dose), Day 12 or 9, and early termination.

  14. Safety and Tolerability - 12-Lead ECG

    Changes from baseline in QRS duration

    Time frame: Screening, Day -1, Day 1 (pre-dose and 2h post-dose), Day 3, Day 6 (Part A), Day 10/7 (pre-dose and 2h post-dose), Day 12/9, and early termination.

  15. Safety and Tolerability - 12 Lead ECG

    Changes from baseline in QT interval

    Time frame: Screening, Day -1, Day 1 (pre-dose and 2h post-dose), Day 3, Day 6 (Part A), Day 10 or 7 (pre-dose and 2h post-dose), Day 12 or 9, and early termination.

  16. Safety and Tolerability - 12 Lead ECG

    Changes from baseline in QTcF interval.

    Time frame: Screening, Day -1, Day 1 (pre-dose and 2h post-dose), Day 3, Day 6 (Part A), Day 10 or 7 (pre-dose and 2h post-dose), Day 12 or 9, and early termination.

  17. Safety and Tolerability - 12 Lead ECG

    Changes from baseline in heart rate.

    Time frame: Screening, Day -1, Day 1 (pre-dose and 2h post-dose), Day 3, Day 6 (Part A), Day 10 or 7 (pre-dose and 2h post-dose), Day 12 or 9, and early termination.

  18. Safety and Tolerability - Vital Signs

    Changes from baseline in systolic and diastolic blood pressure

    Time frame: Screening, Day -1, Day 1 and co-administration day (pre-dose, 2h and 6h post-dose), Day 2, Day 3-9 or 11 (daily), Day 12 or 9, and early termination.

  19. Safety and Tolerability - Vital Signs

    Changes from baseline in pulse rate.

    Time frame: Screening, Day -1, Day 1 and co-administration day (pre-dose, 2h and 6h post-dose), Day 2, Day 3-9 or 11 (daily), Day 12 or 9, and early termination.

  20. Safety and Tolerability - Vital Signs

    Changes from baseline in body temperature.

    Time frame: Screening, Day -1, Day 1 and co-administration day (pre-dose, 2h and 6h post-dose), Day 2, Day 3-9 or 11 (daily), Day 12 or 9, and early termination.

  21. Safety and Tolerability - Physical Examination

    Clinically significant abnormalities in general physical examination.

    Time frame: Screening, Day -1, Day 3, co-administration day (Day 10 or 7), Day 12 or 9, and early termination.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2026
First posted
Apr 24, 2026
StartEst.
May 6, 2026
Primary completionEst.
May 31, 2026
CompletionEst.
Jun 8, 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07550621
Lead sponsor
MindRank AI Ltd
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
May 6, 2026 (estimated)
Primary completion
May 31, 2026 (estimated)
Completion
Jun 8, 2026 (estimated)
Last update
Apr 24, 2026

Study contacts

Guodong Li, PhD
Contact
guodong.li@mindrank.cn
+8618968027256
Adam A. H. Baidoo, MD
Contact
adam@mindrank.cn
+8615658610670
Xiaojiao Li, MD
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MDR-001

Start the discussion